LY-M003 injection for adults with Wilson's disease
Tests a one-time LY-M003 injection in adults with Wilson's disease.
Key facts
- Who runs it
- Lingyi Biotech Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 18 people, planned
- Started
- 15 Jun 2026
- Expected to end
- 30 Dec 2032
- Type of study
- Interventional, 3 groups
- Treatments tested
- LY-M003 Injection
- Record updated
- 2 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Wilson's disease who are already on standard treatment. They get a single dose of the gene therapy LY-M003 Injection.
- Age
- 18 Years to 60 Years
- Sex
- All sexes
- Disease stage
- Confirmed Wilson's disease. People with decompensated cirrhosis or advanced liver disease, or a MELD score > 13, cannot join.
- Earlier treatment
- At least 6 months of standard therapy (for example D-penicillamine or zinc acetate) and at least 6 months of a low-copper diet before screening. No earlier gene therapy or cell therapy.
- Biomarker or test result
- Lab test showing a biallelic ATP7B gene mutation or deletion (both copies of the gene changed or missing). AAV8 neutralizing antibody titer must not be > 1:10.
Main reasons for not taking part
- Decompensated liver cirrhosis or advanced liver disease, or other liver diseases
- Positive test for hepatitis B, hepatitis C, HIV or syphilis
- Kidney disease on dialysis, or creatinine clearance < 60 mL/min
- Past or planned bone marrow, stem cell or organ transplant
- Pregnant or breastfeeding women, or women planning pregnancy
The registry criteria, word for word
Show all 33 criteriaShow less
Who can take part
- The subject fully comprehends the purpose, design, methods and possible adverse events of the study, agrees to participate voluntarily and signs the informed consent form (ICF)
- Patients with confirmed diagnosis of Wilson's disease (WD)
- Subjects with Wilson's disease (WD) confirmed by laboratory testing to have biallelic ATP7B gene mutation or deletion
- The subjects are treated patients with Wilson's disease (WD) who have received standard therapy (e.g., D-penicillamine or zinc acetate) continuously for at least 6 months prior to screening
- Subjects have maintained a low-copper diet for at least 6 consecutive months prior to screening and will continue this dietary restriction throughout the study
- Subjects must agree to refrain from donating blood, organs, tissues or cells at any time after treatment
- Female subjects of childbearing potential (WOCBP) must have a negative pregnancy test
- Subjects and their partners must have no plans for pregnancy from screening through 6 months after study completion, and will voluntarily use effective contraception (e.g., abstinence, condoms). Subjects shall not plan to donate sperm or ova
Who cannot take part
- AAV8 neutralizing antibody titer > 1:10
- Subjects with other concomitant liver diseases as judged by the investigator, including autoimmune hepatitis, alcoholic liver disease, primary biliary cholangitis, primary sclerosing cholangitis, and/or drug- or toxin-induced liver disease
- A history of non-compliance with copper chelators or zinc agents as assessed by the investigator within 6 months prior to screening
- Subjects who have received or plan to undergo bone marrow transplantation, hematopoietic stem cell transplantation and/or major organ transplantation, including but not limited to liver transplantation and renal transplantation
- Subjects with uncontrolled concomitant diseases or infectious diseases as assessed by the investigator
- Prior receipt of any type of gene therapy or cell therapy
- Use of systemic immunosuppressants or steroids within 3 months prior to administration (except for prophylactic immunosuppressive therapy specified in the protocol)
- Received live attenuated vaccines within 4 months prior to screening, or planned to receive such vaccines during the clinical trial
- Received treatment or intervention with other investigational drugs or study devices within 28 days or 5 half-lives (for drugs only) prior to screening, whichever is longer
- History of active gastrointestinal bleeding within the past 3 months
- Decompensated liver cirrhosis or advanced liver disease presenting with portal hypertension, ascites, splenomegaly, esophageal varices, hepatic encephalopathy, etc
- Model for End-Stage Liver Disease (MELD) score > 13
- Other disorders of copper metabolism, such as chronic cholestatic liver diseases, disorders of glycosylation, copper metabolism disorders, etc
- Subjects with positive hepatitis B surface antigen (HBsAg), positive hepatitis C virus (HCV) antibody, positive human immunodeficiency virus (HIV) antibody or positive treponema pallidum antibody
- Subjects with clinically diagnosed severe cardiovascular diseases or those deemed by the investigator to have such conditions (e.g., New York Heart Association [NYHA] heart failure classification ≥ Class 3)
- Subjects who are allergic to any ingredient of LY-M003 Injection
- History of cancer within 5 years prior to screening, excluding completely resected non-melanoma skin cancer, non-metastatic prostate cancer and fully cured ductal carcinoma in situ
- Other conditions that, in the investigator's opinion, render the subject ineligible for study participation
- Previously treated WD subjects with ALT and/or AST levels more than 5 times the upper limit of normal (ULN)
- Hemoglobin < 90g/L
- Subjects with end-stage renal disease on dialysis (Chronic Kidney Disease Stage 3 and above), or creatinine clearance < 60 mL/min
- Severe hyperlipidemia (triglycerides >1000 mg/dL)
- Subjects with severe hypersplenism complicated and requiring splenectomy as assessed by the investigator
- Subjects with severe neurological deficits or impairments that, in the investigator's judgment, compromise their safety and/or ability to participate in the study
- Pregnant women (or women planning pregnancy) or breastfeeding women
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, open-label, single-arm, single-dose Phase I/II clinical study. It aims to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of LY-M003 Injection in patients with Wilson's Disease (WD).
The 3 groups in the trial
- Phase 1: LY-M003 Dose group 1Treatment being tested
Treatment: LY-M003 Injection
- Phase 1: LY-M003 de-escalation doseTreatment being tested
Treatment: LY-M003 Injection
- Phase 2: LY-M003 Dose group 1Treatment being tested
Treatment: LY-M003 Injection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Open, Single-arm, Single-dose, Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease
- Plain-language title
- LY-M003 injection for adults with Wilson's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07641140, who can take part
- Record updated
- 2 July 2026